Alexion Pharmaceuticals, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN) breached their fiduciary duties to shareholders. Alexion, a biopharmaceutical company, develops and commercializes life-transforming therapeutic products.

Alexion Under Investigation By the U.S. Health Inspector General

Alexion is under investigation by the U.S. Department of Health and Human Services’ Office of Inspector General related to a probe by the U.S. Attorney’s Office for the District of Massachusetts and the Department of Justice concerning the company’s support for charities that aid Medicare patients. A Bloomberg investigation in May found a widespread culture of aggressive sales at Alexion aimed at seeking new potential customers and keeping patients on Alexion’s main drug, Soliris. Alexion also disclosed that it is under investigation by the U.S. Securities and Exchange Commission and Department of Justice for issues related to the Foreign Corrupt Practices Act in Brazil.

Alexion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, or you can complete the form below and we will contact you directly.


Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information

    Send This Post